Problems viewing this newsletter? View it in your browser >

New Resources at and Our Webinar Series Continues

March 14, 2016

Dear Advocates,

There’s lots to digest from the recent 2016 Conference on Retroviruses and Opportunistic Infections, but we’ve got you covered. Here are some new resources on our website. Also our post-CROI webinar series continues. See below for details.

ReadAdvocates' Voices from CROI
CROI was about more than the ring results. In our blog series, read perspectives directly from from advocates and activists in attendance. You won’t want to miss advocates' frank takes on which scientists walk the walk in community engagement, why research results are just the beginning and what the ring results means to African women.

ListenWebinar: Exploring Dapivirine Trial Results
In the first of a series, Jared Baeten of the Microbicide Trials Network and Zeda Rosenberg of the International Partnership for Microbicides spoke about the dapivirine ring trial results announced at the conference and fielded questions from webinar participants. (More post-CROI webinars to come! See below.)

LookInfographic: Evidence for HIV Prevention Options
Given these results, what’s the big picture of ARV-based prevention trial results? This graphic shows the levels of efficacy from each major trial with the confidence intervals around the finding. (Not sure what a confidence interval is? See our one-page Advocates' Guide to Statistical Terms.)

ReadDapivirine Ring Results
Two trials of a vaginal ring containing the antiretroviral drug dapivirine announced their results at the conference. We compiled press releases, media reaction, provided background materials, linked to the conference webcasts with the results and more.

We welcome your questions and comments. Get in touch at



Harnessing Antibodies for HIV Prevention and Treatment Thursday, March 17, 9am Eastern
John Mascola from the NIH Vaccine Research Center will build on his CROI plenary, Harnessing Antibodies for HIV-1 Prevention and Treatment.


Long-Acting Injectable Antiretrovirals for Treatment and Prevention Thursday, March 24, 10am Eastern
David Margolis (ViiV Healthcare) and Marty Markowitz (Aaron Diamond AIDS Research Center) will discuss data they presented at CROI 2016. Margolis presented findings from the LATTE 2 trial, which tested a pair of long-acting injectables—cabotegravir (from ViiV Healthcare) and rilpivarine (from Janssen)—for HIV maintenance therapy. Markowitz presented findings from the ÉCLAIR Phase 2A study of cabotegravir in HIV-uninfected men.


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 

Contact Us T: +1 212 796 6423